Most actionable first. Assess the next decision, not the size of the database.
877 matching trial–asset observations. These are not unique or cleared acquisitions. 0 have all four gates supported in this view; entered assessments still require review.
WATCH · SUSPENDED
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous...
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT Other - Assessing accrual feasibility
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
Other - Assessing accrual feasibility
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-09-01. Registry source
WATCH · SUSPENDED
Locally Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT Other - planned analysis of safety and efficacy data
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
Other - planned analysis of safety and efficacy data
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-08-31. Registry source
WATCH · WITHDRAWN
Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8,...
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT Lack of funding
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
Lack of funding
Why stranded: Financing failure · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-09-15. Registry source
WATCH · TERMINATED
Prostate Cancer
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT UNKNOWN
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
UNKNOWN
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2006-02-02. Registry source
WATCH · SUSPENDED
HIV-1-infection
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT Temporarily Closed (Paused) to Accrual and Study Agents/Products
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
Temporarily Closed (Paused) to Accrual and Study Agents/Products
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-09-02. Registry source
WATCH · SUSPENDED
HIV-1-infection
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT Temporarily Closed (Paused) to Accrual and Study Agents/Products
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
Temporarily Closed (Paused) to Accrual and Study Agents/Products
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-09-02. Registry source
WATCH · SUSPENDED
Non-small Cell Lung Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Pancreas Cancer
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT Currently no funding to continue study.
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
Currently no funding to continue study.
Why stranded: Financing failure · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-09-18. Registry source
WATCH · SUSPENDED
Malaria
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT At the end of the year 2002, Cameroon switched from chloroquine to amodiaquine as first-line therapy for of uncomplicated malaria.
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
At the end of the year 2002, Cameroon switched from chloroquine to amodiaquine as first-line therapy for of uncomplicated malaria.
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2007-03-01. Registry source
WATCH · TERMINATED
AIDS Related Lymphoma
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT UNKNOWN
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
UNKNOWN
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2005-08-17. Registry source
WATCH · TERMINATED
Type 2 Diabetes
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT Issues w/recruitment
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
Issues w/recruitment
Why stranded: Recruitment/execution failure · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2007-10-31. Registry source
WATCH · WITHDRAWN
Congenital Adrenal Hyperplasia
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT Protocol re-design required following EU Phase III results
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
Protocol re-design required following EU Phase III results
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-09-14. Registry source
WATCH · WITHDRAWN
Acute Uncomplicated Diverticulitis
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN
SOURCE FACT Study was never approved by the institutional review board.
Rescueability · inferenceUNKNOWN
Current controlUNKNOWN
Next truth · USD / monthsUNKNOWN / UNKNOWN
Restart · inferenceUNKNOWN
Why this survived: Source-backed stopping context warrants a review, not qualification.
Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.
Principal risk: Transferable rights and decision-quality human evidence remain unresolved.
Investigate opportunitySource, stopping context and uncertainty
Study was never approved by the institutional review board.
Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established
Acquisition range: UNKNOWN · Market Pull: UNKNOWN
Confidence UNKNOWN. Source update 2026-08-31. Registry source